IFC Supports B. Braun Melsungen`s local pharmaceuticals manufacturing in Indonesia
The member of World Bank Group provides a loan to B. Braun Melsungen AG operations in Indonesia.
Washington D.C., July 12, 2016—IFC, a member of the World Bank Group, will provide a loan equal to 450 billion Indonesian Rupiah (approximately 33 million US Dollars) to B. Braun Melsungen AG operations in Indonesia to help finance construction of a local facility for the manufacturing of high-quality Large Volume Parenterals (LVPs).
LVPs are aqueous solutions in sterile containers for infusion therapy used commonly throughout a hospital stay. These products are now largely imported into Indonesia. Because LVPs are intended for intravenous infusion, they must be sterilized through heat. B. Braun, a German company with over 175 years of experience, will produce at a European manufacturing standard, thus transferring high-quality pharmaceutical manufacturing skills in the Indonesian economy.
“There is great need for high quality health goods and services in Indonesia, and we are excited to contribute to improving the supply of safe products required for practically every hospital patient,” said Stephan Soyka, Managing Director of B. Braun in Indonesia. “We are investing in a state-of-the-art manufacturing facility and in the training of our employees to operate at the highest standards.”
Sérgio Pimenta, IFC Director for Manufacturing, Agribusiness and Services, said, “Investments in high-quality medical goods are one example of how the private sector can support public efforts for expanding universal health coverage, like in Indonesia.”
At just three percent of Gross Domestic Product (GDP), Indonesia’s health expenditure per capita is lower than other middle-income countries, and less than half the seven percent level of developed countries. The government introduced universal health coverage, the Jaminan Kesehatan Nasional (JKN) in 2014 with plans to roll it out to the entire population in phases by 2019. Demand for hospital care is expected to rise sharply.
IFC is the world’s largest multilateral investor in private healthcare, managing an active portfolio of about $1.3 billion worth of health investments. IFC investments in service providers, pharmaceuticals and medical technology are aimed at promoting greater access to affordable, high-quality healthcare.
About B. Braun
B. Braun is one of the world's leading manufacturers of medical devices and pharmaceutical products and services. With over 56,000 employees in 64 countries, B. Braun develops high quality product systems and services for users around the world. In 2015, the Group generated sales of approximately €6.13 billion. Every service provided by B. Braun incorporates its entire expertise and the company's deep understanding of users' needs. With its constantly growing portfolio of effective medical care solutions, B. Braun makes a substantial contribution towards protecting and improving people's health.
IFC, a member of the World Bank Group, is the largest global development institution focused on the private sector in emerging markets. Working with 2,000 businesses worldwide, we use our six decades of experience to create opportunity where it’s needed most. In FY15, our long-term investments in developing countries rose to nearly $18 billion, leveraging our capital, expertise and influence to help the private sector end extreme poverty and boost shared prosperity. For more information, visit www.ifc.org